Compare DLX & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLX | NEO |
|---|---|---|
| Founded | 1915 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1994 | 2008 |
| Metric | DLX | NEO |
|---|---|---|
| Price | $22.41 | $11.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $23.00 | $13.38 |
| AVG Volume (30 Days) | 398.8K | ★ 2.4M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | ★ 52.54 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $2,133,200,000.00 | N/A |
| Revenue This Year | $1.35 | $10.63 |
| Revenue Next Year | $1.30 | $9.73 |
| P/E Ratio | $28.86 | ★ N/A |
| Revenue Growth | ★ 0.54 | N/A |
| 52 Week Low | $15.41 | $4.72 |
| 52 Week High | $32.07 | $13.74 |
| Indicator | DLX | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 37.86 | 65.42 |
| Support Level | $22.10 | $11.49 |
| Resistance Level | $23.42 | $11.62 |
| Average True Range (ATR) | 0.85 | 0.63 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 24.60 | 88.69 |
Deluxe Corp is principally a payments and data company. Its reportable segments are: Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment, which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services, as well as financial institution profitability reporting and business incorporation services.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.